Combination targeted drug and immunotherapy for recurrent gynecologic cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have squamous cell carcinoma of the cervix, vagina, or vulva that has come back or spread to other parts of the body.
- You have already tried at least one standard treatment that included platinum chemotherapy and an immunotherapy drug, and you have not had more than 4 prior treatments.
- You are able to take care of yourself and are up and about more than half of the day (ECOG 0 or 1).
- Your cancer has at least one tumor that can be measured on a scan.
- You are not pregnant, are not breastfeeding, and agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a new combination treatment for head and neck cancer. The treatment uses an investigational drug (becotatug vedotin) with an immunotherapy (a checkpoint inhibitor). The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
Hear when a new Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.